var data={"title":"Pegylated interferon (peginterferon) beta-1a: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pegylated interferon (peginterferon) beta-1a: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/749930?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pegylated-interferon-peginterferon-beta-1a-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pegylated interferon (peginterferon) beta-1a: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26143900\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Plegridy;</li>\n      <li>Plegridy Starter Pack</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25591165\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Biological Response Modulator;</li>\n      <li>\n        Immunomodulator, Systemic;</li>\n      <li>\n        Interferon</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26188159\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">\n      <b>Multiple sclerosis:</b> SubQ: Initial: 63 mcg on day 1; 94 mcg on day 15. Maintenance: 125 mcg every 14 days beginning on day 29.  <b>Note:</b> Analgesics and/or antipyretics may help decrease flu-like symptoms during treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26188160\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26188161\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution in severe renal impairment (CrCl &lt;30 mL/minute).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Partially removed (~24%) by hemodialysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26188162\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26143901\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Pen-injector, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Plegridy: 125 mcg/0.5 mL (0.5 mL) [contains mouse (murine) and/or hamster protein]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Plegridy Starter Pack: 63 mcg/0.5 mL &amp; 94 mcg/0.5 mL (1 mL) [contains mouse (murine) and/or hamster protein]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Plegridy: 125 mcg/0.5 mL (0.5 mL) [contains mouse (murine) and/or hamster protein]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Plegridy Starter Pack: 63 mcg/0.5 mL &amp; 94 mcg/0.5 mL (1 mL) [contains mouse (murine) and/or hamster protein]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26143899\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26187979\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM475804.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/8bxp4YrxUVJFUAWh6274giI6N99z5Uyy7eVpMOmOxsUQ==&amp;TOPIC_ID=96689\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM475804.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26188164\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Subcutaneous: Administer subcutaneously in the abdomen, back of the upper arm, or thigh; rotate injection sites; do not inject into area where skin is red, irritated, bruised or scarred.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25590906\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Multiple sclerosis:</b> Treatment of patients with relapsing forms of multiple sclerosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26188558\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Peginterferon beta-1a may be confused with interferon alfa-2b, interferon alfacon-1, interferon beta, interferon gamma-1b, peginterferon alfa-2a, peginterferon alfa-2b</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26525530\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (44%), chills (17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Injection site pruritus (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (66%; severe: 3%), erythema at injection site (62%), pain at injection site (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia (19%), asthenia (13%), arthralgia (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Flu-like symptoms (47%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (45%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Increased body temperature (6%), pain (5%), hyperthermia (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (4%), rash at injection site (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased serum ALT (6%; &gt;5 x ULN: 2%), increased gamma-glutamyl transferase (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (9%), vomiting (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic and oncologic: Decreased white blood cell count (&lt;3 x 10<sup>9</sup>/L: 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum AST (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (to PEG: 7%; neutralizing antibodies &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Hematoma at injection site (3%), swelling at injection site (3%), warm sensation at injection site (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Angioedema, hepatic disease, increased serum transaminases (combined with increased serum bilirubin), severe neutropenia, severe thrombocytopenia, thrombotic microangiopathy tissue necrosis at injection site, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25591167\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to natural or recombinant interferon beta or peginterferon, or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for interferons is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Pregnancy; current severe depression and/or suicidal ideation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26187981\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autoimmune disorders: Idiopathic thrombocytopenia, hyper- and hypothyroidism, and autoimmune hepatitis have been reported. Consider discontinuing treatment in patients who develop a new autoimmune disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: May cause decreased peripheral blood cell counts in all cell lines, including rare instances of pancytopenia and severe thrombocytopenia. Monitor CBC with differential and platelets; monitor patients for infections, bleeding, and symptoms of anemia. Patients with preexisting myelosuppression may need more intensive monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Severe hepatic injury, including hepatitis, autoimmune hepatitis, and severe hepatic failure (rare) have been reported; asymptomatic elevation of hepatic transaminases has also been reported and has recurred upon rechallenge. Monitor for signs and symptoms of hepatic injury.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Anaphylaxis and other serious allergic reactions (eg, angioedema, urticaria) may occur (rare); discontinue therapy if a serious allergic reaction occurs and institute appropriate supportive therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection site reactions: Injection site reactions (eg, injection site erythema, pain, pruritus, edema, necrosis) can occur with subcutaneous use. If necrosis occurs at a single site, avoid administration near the affected area; if multiple lesions occur, discontinue until healing occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuropsychiatric disorders: Depression, suicidal ideation and suicide have been reported; monitor for symptoms of depression and suicidal ideation; consider discontinuing treatment with development of depression or other severe psychiatric symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombotic microangiopathy: Thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura (TTP) or hemolytic uremic syndrome (HUS), has been reported (some fatal) with interferon beta products.  Cases have been reported several weeks to years after initiating therapy. Monitor for new-onset hypertension, thrombocytopenia, renal impairment; discontinue use in patients who develop TMA and manage appropriately (Hunt 2014; Mahe 2013). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Congestive heart failure (CHF), cardiomyopathy, and cardiomyopathy  with CHF may occur in patients receiving interferon beta. Monitor patients with significant cardiac disease for worsening of their cardiac condition during initiation and continuation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in severe renal impairment; increased drug exposure may occur; monitor for adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: May cause seizures; use with caution in patients with a seizure disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product variability: Due to differences in dosage, patients should not change brands of interferon.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744730\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744727\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=96689&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Interferons may decrease the metabolism of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine: Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26714184\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26714183\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events were observed in some animal reproduction studies. Until information is available, consideration should be given to discontinuing treatment prior to pregnancy (Buraga 2014; Coyle 2012; Houtchens 2013; Lu 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A pregnancy registry has been established to monitor outcomes of women exposed to peginterferon beta-1a during pregnancy (866-810-1462 or https://www.plegridypregnancyregistry.com/).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26714186\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;\">It is not known if peginterferon beta-1a is excreted into breast milk. The manufacturer recommends that caution be exercised when administering peginterferon beta-1a to a nursing woman.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26188166\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelets, transaminase levels; signs and symptoms of hepatic injury, hypersensitivity, infections, bleeding, new onset autoimmune disorders, psychiatric disorders (including depression and/or suicidal ideation), new onset/worsening cardiovascular disease; adverse reactions in patients with severe renal impairment (CrCl &lt;30 mL/minute); injection site reactions; signs/symptoms of thrombotic microangiopathy (eg, new-onset hypertension, thrombocytopenia, renal impairment).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26188073\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Interferon beta differs from the naturally occurring human protein by a single amino acid substitution and the lack of carbohydrate side chains; alters the expression and response to surface antigens and can enhance immune cell activities. Properties of interferon beta that modify biologic responses are mediated by cell surface receptor interactions; mechanism in the treatment of multiple sclerosis is unknown.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26191019\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\"> Distribution: V<sub>d</sub>: 481 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Not extensively metabolized in the liver</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~78 hours (multiple sclerosis patients)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: 1 to 1.5 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (major)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26597084\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Pen-injector</b> (Plegridy Starter Pack Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">63 &amp; 94 mcg/0.5 mL (1 mL): $8,147.94</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Pen-injector</b> (Plegridy Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mcg/0.5 mL (0.5 mL): $4,073.97</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Plegridy Starter Pack Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">63 &amp; 94 mcg/0.5 mL (1 mL): $8,147.94</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Plegridy Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mcg/0.5 mL (0.5 mL): $4,073.97</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25871871\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Plegridy (AT, AU, BB, CZ, DE, DK, EE, ES, FR, HR, HU, IS, LT, LU, LV, MT, NL, NO, NZ, PL, PT, RO, SE, SI, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Buraga I, Popovici RE. Multiple sclerosis and pregnancy: current considerations. <i>Scientific World Journal</i>. 2014;2014:513160. doi: 10.1155/2014/513160.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-beta-1a-drug-information/abstract-text/24977202/pubmed\" target=\"_blank\" id=\"24977202\">24977202</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coyle PK. Pregnancy and multiple sclerosis. <i>Neurol Clin</i>. 2012;30(3):877-888. doi: 10.1016/j.ncl.2012.05.002.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-beta-1a-drug-information/abstract-text/22840794/pubmed\" target=\"_blank\" id=\"22840794\">22840794</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Houtchens MK, Kolb CM. Multiple sclerosis and pregnancy: therapeutic considerations. <i>J Neurol</i>. 2013;260(5):1202-1214. doi: 10.1007/s00415-012-6653-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-beta-1a-drug-information/abstract-text/22926165/pubmed\" target=\"_blank\" id=\"22926165\">22926165</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hunt D, Kavanagh D, Drummond I, et al. Thrombotic microangiopathy associated with interferon beta. <i>N Engl J Med</i>. 2014;370(13):1270-1271.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-beta-1a-drug-information/abstract-text/24670186/pubmed\" target=\"_blank\" id=\"24670186\">24670186</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lu E, Wang BW, Guimond C, et al. Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. <i>Expert Rev Neurother</i>. 2013;13(3):251-260; quiz 261. doi: 10.1586/ern.13.12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-beta-1a-drug-information/abstract-text/23448215/pubmed\" target=\"_blank\" id=\"23448215\">23448215</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahe J, Meurette A, Moreau A, et al. Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis. <i>Drug Des Devel Ther</i>. 2013;7:723-728.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-beta-1a-drug-information/abstract-text/23950639/pubmed\" target=\"_blank\" id=\"23950639\">23950639</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Plegridy (peginterferon beta-1a) [prescribing information]. Cambridge, MA: Biogen Idec Inc; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Plegridy (peginterferon beta-1a) [product monograph]. Mississauga, Ontario, Canada: Biogen Canada Inc; June 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 96689 Version 55.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F26143900\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F25591165\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F26188159\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F26188160\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F26188161\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F26188162\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F26143901\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F26143899\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F26187979\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F26188164\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F25590906\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F26188558\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F26525530\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F25591167\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F26187981\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F25744730\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F25744727\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F26714184\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F26714183\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F26714186\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F26188166\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F26188073\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F26191019\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F26597084\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F25871871\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/96689|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pegylated-interferon-peginterferon-beta-1a-patient-drug-information\" class=\"drug drug_patient\">Pegylated interferon (peginterferon) beta-1a: Patient drug information</a></li></ul></div></div>","javascript":null}